Anemia Drugs Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Anemia Drugs Market Size By 2025?
In the past years, the market for anemia drugs has experienced notable growth. Predictions indicate a rise from $14.72 billion in 2024 to $15.77 billion in 2025, which represents a compound annual growth rate (CAGR) of 7.1%. This growth during the historical timeframe is due to factors like the surging incidence of chronic illnesses, heightened awareness about the iron deficiency type of anemia, an increase in the aged population, better accessibility to healthcare in developing areas, and an increased need for focused therapies.

How Big Is the Anemia Drugs Market Size Expected to Grow by 2029?
The market for anemia drugs is projected to witness substantial growth in the coming years, expanding to an estimated worth of $21.09 billion in 2029, with a compound annual growth rate of 7.5%. Factors contributing to this growth for the stipulated period span from an incline in the embrace of personalized medicine and escalated healthcare spending in emerging markets, to an increase in clinical trials for anemia treatments, a worldwide surge in anemia prevalence, and heightened emphasis on patient-oriented drug production. Key trends for this forecast period embrace progress in gene therapy for anemia, enhanced delivery mechanisms for iron supplements, novel developments in erythropoiesis-stimulating agents, cutting-edge tools for diagnosing anemia, and innovations in orally administered anemia treatments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anemia-drugs-global-market-report

Which Key Market Drivers Powering Anemia Drugs Market Expansion and Growth?
The anemia drugs market is anticipated to grow due to the escalating emphasis on personalized medicine. This method of medicine caters to an individual's genetic makeup, lifestyle, and environment to shape treatment and healthcare decisions. The emphasis on individualized medicine is spurred on by advances in genomic sequencing, allowing for the accurate identification of genetic variations linked to both the disease and response to treatment. Personalized medicine boosts anemia drug production through the development of treatments tailored to each person's genetic profile, thereby enhancing drug effectiveness and reducing side effects for improved patient results. The Personalized Medicine Coalition, a non-profit organization based in the U.S., reported in February 2024 that in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients suffering from rare diseases, a remarkable increase from the 6 approved in 2022. Consequently, the growing emphasis on personalized medicine is fueling the expansion of the anemia drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24141&type=smp

What Long-Term Trends Will Define the Future of the Anemia Drugs Market?
Primary businesses involved in the anemia drugs market are putting their focus on the development of innovative treatments such as oral HIF-PHIs (hypoxia-inducible factor prolyl hydroxylase inhibitors) which aim to augment iron metabolism and boost the production of red blood cells, in order to more efficiently treat anemia. The aforementioned oral HIF-PHIs are a type of medication taken by mouth that primarily targets and halts the activities of prolyl hydroxylase enzymes, a crucial component in the control of the hypoxia-inducible factor pathway. For example, February 2023 saw the launch of Jesduvroq by GSK plc, a pharmaceutical firm hailing from the UK, a treatment specifically designed to bolster the production of red blood cells and combat anemia in adults suffering from chronic kidney disease. The innovative drug system used in Jesduvroq enhances iron metabolism and improves the generation of red blood cells, in addition to including personalized therapies. The effectiveness of Jesduvroq is noteworthy, as it significantly increased red blood cell production and effectively treats anemia for those struggling with chronic kidney disease by improving iron metabolism for superior results in their treatment.

What Are the Emerging Segments in the Anemia Drugs Market?
The anemia drugs market covered in this report is segmented -

1) By Drug Type: dietary supplemen*ts, Medicines
2) By Therapy Type: Oral Iron Therapy, Red Blood Cell Transfusion, Parental Iron Therapy, Other Therapy Types
3) By Anemia Type: Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, Others Anemia Type
4) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
5) By End-User: Clinic, Healthcare, Home Healthcare

Subsegments:
1) By dietary supplemen*ts: Iron Supplements, Vitamin B12 Supplements, Folic Acid Supplements, Multivitamin And Mineral Supplements
2) By Medicines: Erythropoiesis-Stimulating Agents (ESAs), Iron Chelating Agents, Corticosteroids, Immunosuppressants, Luspatercept And Related Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24141&type=smp

Who Are the Global Leaders in the Anemia Drugs Market?
Major companies operating in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, Regen Biopharma Inc., BioLineRx Ltd., Bluebird Bio Inc.

Which are the Top Profitable Regional Markets for the Anemia Drugs Industry?
North America was the largest region in the anemia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24141

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.